First Affiliated Hospital of USTC
中国科学技术大学附属第一医院(安徽省立医院)
Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at First Affiliated Hospital of USTC
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌2 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌17 papers led6 open trials led
- Hepatocellular carcinoma肝细胞癌91 papers led4 open trials led
- Stomach cancer胃癌22 papers led
- Osteosarcoma骨肉瘤3 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
- Neuroblastoma神经母细胞瘤4 papers led
- Multiple myeloma多发性骨髓瘤2 papers led2 open trials led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led2 open trials led
- Aplastic anaemia再生障碍性贫血2 papers led1 open trial led
- Haemophilia A血友病 A2 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Fanconi anaemia范可尼贫血0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
- Myasthenia gravis重症肌无力1 paper led
- Moyamoya disease烟雾病5 papers led
- Wilson disease肝豆状核变性(Wilson 病)6 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Fabry disease法布雷病2 papers led
- Behçet disease白塞病0 papers led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
- Congenital diaphragmatic hernia先天性膈疝0 papers led
- Hirschsprung disease先天性巨结肠1 paper led
Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, IgG4-related disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
More papers found outside PubMed (not counted)3
- Unsupervised deep learning model for fast energy layer pre-selection of delivery-efficient proton arc therapy plan optimization of nasopharyngeal carcinoma
- 1498 Safety, tolerability and preliminary efficacy of QLP2117, a novel CCR8 antibody, in patients with advanced solid tumors: results from a dose-escalation phase 1a clinical trial
- Cancer stem-like cells of nasopharyngeal carcinoma express CXCR4 and display highly invasive activity
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 17 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.6%.
4 hospitals in Hefei for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIvonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07188103
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingShort-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
- Phase
- Not given
- Started
- 2024-03
- Registry
- NCT06408584
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingNeoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
- Phase
- N/A
- Started
- 2024-01
- Registry
- NCT06602843
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingWhole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-07
- Registry
- NCT05833594
Age 18 years to 85 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingPostoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Registry
- NCT05937438
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- Not yet recruitingDefinitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07034118
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07405151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Registry
- NCT05319730
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou
- RecruitingValue of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- Phase
- Not given
- Started
- 2022-07
- Registry
- NCT05443841
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led17
- Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients.
- CD49a+ NK cells promote esophageal cancer development by inducing MDCSs infiltration via GM-CSF.
- PC4 Potentially Predicts Chemoradiation-Induced Antitumor Immunity in Esophageal Squamous Cell Carcinoma.
- Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.
- Long non-coding RNA SNHG16 promotes tumor progression and cisplatin resistance in esophageal squamous cell carcinoma via miR-497-5p/HK2 axis.
- FBXL18 increases cell proliferation and reduces cell radiosensitivity in esophageal squamous cell carcinoma.
- GPR37-enhanced ubiquitination of ATP1A1 inhibits tumor progression and radiation resistance in esophageal squamous cell carcinoma.
- A nomogram based on clinical characteristics and nutritional indicators for relative and absolute weight loss during radiotherapy in initially inoperable patients with locally advanced esophageal squamous cell carcinoma.
- Should we pay more attention to the potential link between Helicobacter pylori and esophageal cancer in Asian countries.
- RIG-I Promotes Tumorigenesis and Confers Radioresistance of Esophageal Squamous Cell Carcinoma by Regulating DUSP6.
- Survival analysis of 80 elderly patients with esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy with S-1.
- FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.
- Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
- The Hu antigen R/interferon-β axis modulates sensitivity of esophageal squamous cancer cells to cisplatin.
- A Nutrition and Inflammation-Related Nomogram to Predict Overall Survival in Surgically Resected Esophageal Squamous Cell Carcinoma (ESCC) Patients.
- Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients.
- Upregulation of KCNMA1 facilitates the reversal effect of verapamil on the chemoresistance to cisplatin of esophageal squamous cell carcinoma cells.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status24
- Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
- Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
- Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
- Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
- Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
- Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
- Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)14
- 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical
- Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC):
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
- Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow
- 1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
- Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
- 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
- Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study.
- LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 91 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.
3 hospitals in Hefei for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 14
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingOral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07793695
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingThe Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
- Phase
- Phase 4
- Started
- 2025-11
- Registry
- NCT07150624
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingAdjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06498622
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingLiver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT07782632
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Registry
- NCT07547553
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou
- RecruitingJS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06954467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou
- RecruitingPhase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07176650
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07391839
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- Phase
- Phase 3
- Started
- 2024-10
- Registry
- NCT06618664
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
- Not yet recruitingA Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07239986
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led91
- Contrast-enhanced MRI for Hepatocellular Carcinoma Assessment: Advances in Contrast Agents and Immunotherapy.
- Multi-phase CT-based intratumoral and peritumoral radiomics for predicting tertiary lymphoid structures of hepatocellular carcinoma: a multi-center retrospective cohort study.
- ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis.
- Lactylation-Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib.
- Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study.
- High-throughput screening identifies a dual-activity inhibitor of OXCT1 for hepatocellular carcinoma therapy.
- Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma.
- Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma.
- Nuclear-localized HKDC1 promotes hepatocellular carcinoma through phosphorylating RBBP5 to upregulate H3K4me3.
- HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma.
- CNDP1 Suppresses the Malignant Behavior of Hepatoma Cell via Restricting PI3K-AKT-mTOR Activation.
- ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway.
- Exosomes Derived from Endoplasmic Reticulum Stressed Hepatocellular Carcinoma Cells Enhance the Antitumor Immunity of Dendritic Cells.
- Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway.
- HnRNPR-mediated UPF3B mRNA splicing drives hepatocellular carcinoma metastasis.
- An Integrated Model Combined Conventional Radiomics and Deep Learning Features to Predict Early Recurrence of Hepatocellular Carcinoma Eligible for Curative Ablation: A Multicenter Cohort Study.
- Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
- Predicting Immunotherapy Response in Unresectable Hepatocellular Carcinoma: A Comparative Study of Large Language Models and Human Experts.
- Long noncoding RNA RHPN1-AS1 promotes hepatocellular carcinoma progression under hypoxia through interaction with RPS15A protein.
- Inhibition of glutamine synthetase enhances hepatocellular carcinoma radiosensitivity through ROS-induced excessive mitophagy.
- A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy.
- Spatial immune scoring system predicts hepatocellular carcinoma recurrence.
- RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma.
- Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens.
- PDHX acetylation facilitates tumor progression by disrupting PDC assembly and activating lactylation-mediated gene expression.
- VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment.
- Toxin protein LukS-PV targeting complement receptor C5aR1 inhibits cell proliferation in hepatocellular carcinoma via the HDAC7-Wnt/β-catenin axis.
- Minimally Invasive Delivery of Percutaneous Ablation Agent via Magnetic Colloidal Hydrogel Injection for Treatment of Hepatocellular Carcinoma.
- A Mammalian Conserved Circular RNA CircLARP1B Regulates Hepatocellular Carcinoma Metastasis and Lipid Metabolism.
- Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
- Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.
- Apigenin inhibits tumor angiogenesis by hindering microvesicle biogenesis via ARHGEF1.
- LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity.
- Diagnostic value of carbohydrate antigen 50 in biliary tract cancer: A large-scale multicenter study.
- Activation of CTU2 expression by LXR promotes the development of hepatocellular carcinoma.
- Energy stress-induced circDDX21 promotes glycolysis and facilitates hepatocellular carcinogenesis.
- Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC.
- FIGNL1 Promotes Hepatocellular Carcinoma Formation via Remodeling ECM-receptor Interaction Pathway Mediated by HMMR.
- NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
- LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche.
- Upregulation of FAM134B inhibits endoplasmic reticulum stress-related degradation protein expression and promotes hepatocellular carcinogenesis.
- Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma.
- OXCT1 functions as a succinyltransferase, contributing to hepatocellular carcinoma via succinylating LACTB.
- Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors.
- Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion.
- Evaluating microvascular invasion in hepatitis B virus-related hepatocellular carcinoma based on contrast-enhanced computed tomography radiomics and clinicoradiological factors.
- Computed tomography-based radiomics to predict early recurrence of hepatocellular carcinoma post-hepatectomy in patients background on cirrhosis.
- Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.
- Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression.
- Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
- Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study.
- Retroperitoneal Laparoscopic Hepatectomy for a Subcapsular Hepatocellular Carcinoma in Segment VI (Video).
- Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
- Copper in hepatocellular carcinoma: A double-edged sword with therapeutic potentials.
- Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
- UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma.
- LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11-dependent repression of CDKN2A.
- Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
- SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth.
- LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma.
- Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
- KIAA1429 protects hepatocellular carcinoma cells from ferroptotic cell death with a m6 A-dependent posttranscriptional modification of SLC7A11.
- Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
- Effects of indocyanine green fluorescence imaging of laparoscopic anatomic liver resection for HCC: a propensity score-matched study.
- Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma.
- Predictive value of radiomics analysis of enhanced CT for three-tiered microvascular invasion grading in hepatocellular carcinoma.
- Secreted protease PRSS35 suppresses hepatocellular carcinoma by disabling CXCL2-mediated neutrophil extracellular traps.
- LukS-PV inhibits hepatocellular carcinoma cells migration by downregulating HDAC6 expression.
- Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study.
- Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing.
- Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression.
- LukS-PV inhibits the proliferation of hepatocellular carcinoma cells by maintaining FOXO3 stability via the PI3K/AKT signaling pathway.
- Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
- Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
- The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications.
- Clinical effectiveness of transcatheter arterial chemoembolization sequential microwave ablation for lack of blood supply in hepatocellular carcinoma.
- Al18F-NOTA-FAPI-04 outperforms 18F-FDG PET/CT in imaging for intrahepatic metastasis of hepatocellular carcinoma.
- Interactive Relationships between Intestinal Flora and Bile Acids.
- MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation.
- Application of Indocyanine Green Fluorescence Imaging Combined with Laparoscopic Ultrasound in Laparoscopic Microwave Ablation of Liver Cancer.
- ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1.
- Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
- Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
- Chronic alcohol exposure promotes HCC stemness and metastasis through β-catenin/miR-22-3p/TET2 axis.
- Body Composition Changes in Hepatocellular Carcinoma: Prediction of Survival to Transcatheter Arterial Chemoembolization in Combination With Clinical Prognostic Factors.
- Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis.
- Circular RNA circZFR Promotes Hepatocellular Carcinoma Progression by Regulating miR-375/HMGA2 Axis.
- ASIC1a promotes acidic microenvironment-induced HCC cells migration and invasion by inducing autophagy.
- Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
- Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis.
- An Orthotopic Liver Transplantation Patient Survived Without Hepatic Artery Flow Due to Thrombosis: A Case Report.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status43
- Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
- The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
- Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
- Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
- Precision Dietary Intervention Improves Postoperative Energy Intake, Nutritional Status, and Recovery in Patients Undergoing Hepatectomy for Liver Cancer: A Randomized Controlled Trial
- "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma
- A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
- HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
- Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
- MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
- PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study
- Impact of Hepatectomy on HCC Recurrence
- A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Cancer
Stomach cancer
胃癌Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Hefei for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingS-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03941561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- The LGALS9/miR-491-5p Axis Regulates CD8+ T Cell Function and Inhibits the Progression of Gastric Cancer.
- Acidic tumor microenvironment-modulated nanoparticle potentiates gastric cancer photoimmunotherapy.
- Patient-Reported Outcome-Based Symptom Management Improves Quality of Life in Postoperative Gastroesophageal Cancer Patients: A Randomized Controlled Trial.
- Parthenolide induces ROS-dependent cell death in human gastric cancer cell.
- Identification of hepatitis B virus infection and integration and its oncogenic role in gastric cancer.
- Pretreatment lymphocyte-monocyte ratio (LMR) as a superior predictor of short-term progression outcomes in patients with gastric cancer receiving second- and later-line apatinib regimens.
- Famine Exposure during Early Life and Risk of Cancer in Adulthood: A Systematic Review and Meta-Analysis.
- Analysis of gastric microbiome reveals three distinctive microbial communities associated with the occurrence of gastric cancer.
- Hand-assisted laparoscopic resection versus total laparoscopic gastric surgery for primary gastric gastrointestinal stromal tumors (GISTs): an analysis from a high-volume institution.
- Serological and Molecular Characterization of Hepatitis B Virus Infection in Gastric Cancer.
- Elevation of ADAM12 facilitates tumor progression by enhancing metastasis and immune infiltration in gastric cancer.
- Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance.
- Use of proton pump inhibitors for the risk of gastric cancer.
- Preoperative prediction for lymph node metastasis in early gastric cancer by interpretable machine learning models: A multicenter study.
- A Nomogram Combining Neutrophil-to-Lymphocyte Ratio and D-Dimer Predicts Chemosensitivity of Oxaliplatin-Based First-Line Chemotherapy in Patients with Unresectable Advanced Gastric Cancer.
- Famotidine promotes inflammation by triggering cell pyroptosis in gastric cancer cells.
- Long non-coding RNA BX357664 inhibits gastric cancer progression by sponging miR-183a-3p to regulate the PTEN expression and PI3K/AKT pathway.
- Gastrointestinal Microbiota Changes in Patients With Gastric Precancerous Lesions.
- Knockdown of CENPK inhibits cell growth and facilitates apoptosis via PTEN-PI3K-AKT signalling pathway in gastric cancer.
- Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening.
- A WNT7B-m6A-TCF7L2 positive feedback loop promotes gastric cancer progression and metastasis.
- Endoscopic obturation with tissue adhesive for bleeding gastric stromal tumor: a case report.
All its trials on ClinicalTrials.gov, any status18
- XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
- Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
- XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
- Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Hefei for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- LAMTOR5-AS1 Regulates Chemotherapy-induced Oxidative Stress via the miR-34a-3p/SIRT1/HNF4A Axis in Osteosarcoma Cells.
- LAMTOR5-AS1 regulates chemotherapy-induced oxidative stress by controlling the expression level and transcriptional activity of NRF2 in osteosarcoma cells.
- A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy.
Earlier papers (2016–2020)7
- Doxorubicin and CD‑CUR inclusion complex co‑loaded in thermosensitive hydrogel PLGA‑PEG‑PLGA localized administration for osteosarcoma.
- MicroRNA‑330‑5p inhibits osteosarcoma cell growth and invasion by targeting the proto‑oncogene survivin.
- The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
- MiR-34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene.
- Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A.
- High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.
- MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hefei for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- A deep-learning model for predicting tyrosine kinase inhibitor response from histology in gastrointestinal stromal tumor.
- Hand-assisted laparoscopic resection versus total laparoscopic gastric surgery for primary gastric gastrointestinal stromal tumors (GISTs): an analysis from a high-volume institution.
- Stromal composition predicts relapse of early rectal cancer after local resection: several methodological concerns.
- Endoscopic obturation with tissue adhesive for bleeding gastric stromal tumor: a case report.
Cancer
Neuroblastoma
神经母细胞瘤Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hefei for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Promoting application of enhanced recovery after surgery protocols during perioperative localized abdominal and thoracic neuroblastomas.
- Retroperitoneal localized neuroblastoma in children: a comparison of enhanced recovery after surgery versus traditional care.
- Differential expression and significance of miRNAs in plasma extracellular vesicles of patients with Parkinson's disease.
- LncRNA HCP5 promotes neuroblastoma proliferation by regulating miR-186-5p/MAP3K2 signal axis.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.
4 hospitals in Hefei for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingSafety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT07085559
Age 19 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hefei for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status6
- Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
- QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for aplastic anaemia63 hospitals in China for aplastic anaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingConditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
- Phase
- Phase 2
- Started
- 2027-08
- Registry
- NCT07885982
Age 1 year to 50 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
- Upfront Umbilical Cord Blood Transplantation Versus Immunosuppressive Therapy for Pediatric Patients With Idiopathic Severe Aplastic Anemia.
- Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Chinese-language papers (not in the count)2
- [Single non-blood-related umbilical cord blood transplantation using a reduced-intensity conditioning regimen for the treatment of severe aplastic anemia].
- [The reduced intensity conditioning of single umbilical cord blood transplantation in the treatment of Fanconi anemia: a report of three cases and literature review].
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Haemophilia A
血友病 ALed 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Hefei for haemophilia A132 hospitals in China for haemophilia A
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTo Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06833983
Age 18 years to 65 years; men only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
- RecruitingAn Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Phase
- Phase 1/Phase 2
- Started
- 2024-05
- Registry
- NCT07644832
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Hefei, Jinan, Lanzhou, Taiyuan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status15
- To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Evaluate Efficacy and Safety of Recombinant Factor VIII (rFVIII)Treatment of Severe or Moderately Severe Hemophilia A
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hefei for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led no English-language PubMed papers on Fanconi anaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Hefei for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Myasthenia gravis
重症肌无力Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Hefei for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingEfficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
- Phase
- Phase 1
- Started
- 2026-12
- Registry
- NCT07556120
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status4
- Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 5 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hefei for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- Desmoglein-2 Affects Vascular Function in Moyamoya Disease by Interacting with MMP-9 and Influencing PI3K Signaling.
- ABO blood types may affect transient neurological events after surgical revascularization in patients with moyamoya disease: a retrospective single center study.
- Classify patients with Moyamoya disease according to their cognitive performance might be helpful in clinical and practical with support vector machine based on hypergraph.
- Surgical revascularization vs. conservative treatment for adult hemorrhagic moyamoya disease: analysis of rebleeding in 322 consecutive patients.
- Individualized Perioperative Blood Pressure Management for Adult Moyamoya Disease: Experience from 186 Consecutive Procedures.
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 6 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 3.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hefei for Wilson disease28 hospitals in China for Wilson disease
No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led6
- Free Water MRI of White Matter in Wilson's Disease.
- Neuroimaging Correlates with Clinical Severity in Wilson Disease: A Multiparametric Quantitative Brain MRI.
- Berberine alleviates ovarian tissue damage in mice with hepatolenticular degeneration by suppressing ferroptosis and endoplasmic reticulum stress.
- NK cell exhaustion in Wilson's disease revealed by single-cell RNA sequencing predicts the prognosis of cholecystitis.
- A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson's disease.
- Platelet safety range before splenectomy for hypersplenism: based on 244 cases of splenectomy in hepatolenticular degeneration patients.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Hefei for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status5
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hefei for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Fabry disease
法布雷病Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Hefei for Fabry disease80 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hefei for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hefei for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
IgA nephropathy
IgA 肾病Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hefei for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Hefei for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hefei for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led no English-language PubMed papers on congenital diaphragmatic hernia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hefei for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Hirschsprung disease
先天性巨结肠Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hefei for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Getting in touch
Name card to show staff or a driver
中国科学技术大学附属第一医院(安徽省立医院)
First Affiliated Hospital of USTC
合肥
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
First Affiliated Hospital of USTC; Anhui Provincial Hospital; Anhui Provincial Hospital Affiliated to Anhui Medical University; Affiliated Anhui Provincial Hospital of Anhui Medical University; Guoyang Branch of Anhui Provincial Hospital; West Branch of The First Affiliated Hospital of USTC; West District of The First Affiliated Hospital of USTC; Anhui Provincial Hospital Affiliated with Anhui Medical University